Expanding MRD testing to more patients with colorectal cancer
Giving clinicians more Latitude™ with MRD testing
Latitude™ is a tissue-free, blood-based, residual disease test (MRD) that delivers fast and reliable results without the need for tumor tissue. It is built on Natera’s MRD expertise and offers high concordance with Signatera™ in comparative analysis, built using a targeted panel composed of differentially methylated regions specifically for colorectal cancer (CRC).
Latitude™ status post-operatively is highly prognostic
The Clinical performance in a 200 patient, 1300+ samples CRC study using samples from the CIRCULATE-JAPAN GALAXY Study
- Patients who tested negative with Latitude™ had significantly longer DFS compared to those who tested positive. HR ratio of 10, p<0.001
- 58% MRD time point sensitivity
- 81% longitudinal sensitivity (84% colon only)
- 97% Sample Level Specificity
- 4.6 months lead time before radiographic relapse
Determine which patients will benefit from ACT
- Patients who were Latitude™ negative receive little benefit from ACT while Latitude™ positive patients had longer DFS
- Latitude™ positive patients who did not receive ACT went on to relapse representing a PPV of 100% (26/26)
When to use Latitude™
- When Signatera™ cannot be performed due to tissue limitations, reflex to Latitude™ with the sample on hand to ensure patients still receive MRD results. We will continue to try and build Signatera™ if possible, but if not the patient can continue with Latitude™ for serial testing.
- When tissue isn’t available, Latitude™ offers a reliable tissue-free MRD solution.
- When clinicians need answers fast, Latitude™ and Signatera™ can be ordered at the same time. To enable time for critical adjuvant treatment decisions.